Regardless of treatment, cancer doesn’t always go away
A new meta-analysis study reveals that complete response rate to chemotherapy treatment remain low to common types of late-stage cancer despite of new treatment methods.
What challenges do survivors of childhood or young adult cancer face?
Two recent clinical studies shed light on the health challenges faced by survivors of childhood or young adult cancer.
New treatment for acute lymphoblastic leukemia approved in EU
EU regulators approved blinatumomab for the treatment of adults with Philadelphia chromosome-negative relapsed or refractory B-precursor acute lymphoblastic leukemia.
FDA approved immunotherapy drug Opdivo to treat kidney cancer
U.S. regulators approved Bristol-Myers Squibb's immunotherapy drug Opdivo for the treatment of patients with advanced (metastatic) renal cell carcinoma.
Treatment for non-small cell lung cancer gets FDA approval
US regulators approved the monoclonal antibody necitumumab Portrazza as a first-line treatment for advanced squamous non-small cell lung cancer.
New treatment holds promise for brain cancer patients
Brain cancer patients survived longer when treated with Optune in combination with Avastin, a new late-stage study reveals.
FDA approves drug combination for skin cancer
U.S. regulators approved Novartis’ drug combination of Tafinlar and Mekinist for the treatment of metastatic melanoma.
Extended survival with combination treatment in skin cancer
Combing cobimetinib and vemurafenib extended the survival rate of previously untreated patients with advanced skin cancer, a new study reports.
EU approves combination therapy for relapsed multiple myeloma
European regulators approved carfilzomib in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma.
Pancreatic cancer immunotherapy shows promise in melanoma
According to latest five year survival clinical results, patients with metastatic melanoma were benefited by IMM-101, a pancreatic cancer immunotherapy drug.
New oral treatment approved for myeloma
Takeda’s oral myeloma treatment, ixazomib (Ninlaro), got approved by the FDA as a second-line combination therapy.
Positive results from immunotherapy in metastatic bladder cancer
Investigational immunotherapy increased overall survival in patients with metastatic bladder cancer, according to a new study.
One step closer to the treatment of Merkel cell carcinoma
U.S. regulators granted breakthrough therapy designation to avelumab for the treatment of patients with metastatic Merkel cell carcinoma.
New study sheds light to colorectal cancer recurrence
A new study comes to explain why metastatic colorectal cancer comes back after treatment with cetuximab to some patients.
The benefits of yoga for prostate cancer patients
Taking intensive yoga classes helped patients undergoing prostate cancer treatment improve their general well-being, a new research shows.
Immunotherapy gets U.S. approval for advanced multiple myeloma
The FDA approved Johnson & Johnson’s immunotherapy drug, Darzalex (daratumumab) for the treatment of patients with advanced multiple myeloma.
Psychological factors and nausea during cancer therapy
A new study reveals the relationship between psychological factors and nausea and vomiting during chemotherapy of cancer.
New FDA approved treatment for non-small cell lung cancer
U.S. regulators approved osimertinib for the treatment of metastatic epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer.
Combination therapy gives hope to mantle cell lymphoma patients
Patients with mantle cell lymphoma benefited from the drug combination of rituximab plus lenalidomide, a new study shows.
Birth control pills tied to increased survival in ovarian cancer
Ovarian cancer patients who had previously taken birth control pills had improved progression-free survival according to a new study.
New treatment approved for advanced melanoma
The U.S FDA approved Cotellic for the treatment of patients with untreated BRAF V600 mutation-positive advanced melanoma.
Lung cancer surgery: a beneficial option for high-risk patients
A new study revealed the effectiveness and the safety profile of surgical lung resection for high-risk patients with early stage lung cancer.
A melanoma treatment appears affective in BRAF-mutant brain tumor
A patient with a BRAF-mutant brain tumor benefited from the melanoma treatment, dabrafenib, revealing the potential of the drug against this type of brain tumor.
Positive patient outcomes with immunotherapy in bladder cancer
An investigational immunotherapy appears effective in treating patients with metastatic urothelial cancer, two recent trials report.
Chemotherapy linked to long-term neurocognitive deficits
Neuroscientists report that permanent hearing loss resulting from chemotherapy may contribute to long-term neurocognitive deficits in pediatric brain tumor survivors.
Vemurafenib appears effective in hairy cell leukemia
A short course of oral vemurafenib was found to be highly effective in patients with relapsed/refractory hairy cell leukemia, two separate, phase 2 studies reveal.
Is radiotherapy effective in treating liver cancer?
Treating liver cancer patients with higher doses of radiotherapy increased long-term survival rates that compare favorably with resection, a study showed.
Gene-targeted drug against prostate cancer
Olaparib, a drug against inherited cancer mutations, was found to benefit as many as a third of patients with prostate cancer, a new study reveals.
Is there a connection between exercise and breast cancer risk?
Women at high-risk of breast cancer could benefit from regular physical activity, according to a new research.
Combo treatment promising for metastatic renal cell carcinoma
Patients of renal cell carcinoma benefited significantly when treated with a combination of lenvatinib with everolimus, a new phase 2 study reveals.